Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts

Journal of Urology

Volumn 170, Issue 4 I, 2003, Pages 1388-1393

  Abraham, Dietmar ^a   Abri, Samad ^a   Hofmann, Michael ^a   Höltl, Wolfgang ^b   Aharinejad, Seyedhossein ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b KFJ Hospital   (Austria)

Author keywords

Angiogenesis; Carboplatin; Germinoma; Mice, SCID; Testis

Indexed keywords

CARBOPLATIN; ENDOSTATIN; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIAL GROWTH FACTOR A; MESSENGER RNA; RINGER SOLUTION; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; GERM CELL TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE; TIME SERIES ANALYSIS; XENOGRAFT;

EID: 0042692888     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000075917.98929.57     Document Type: Article

References (16)

1. Bosl, G. J. and Motzer, R. J.: Testicular germ-cell cancer. N Engl J Med, 337: 242, 1997
2. Bajorin, D. F., Sarosdy, M. F., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I. et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol, 11: 598, 1993
3. Tscherry, G., Jacky, E., Jost, L. M. and Stahel, R. A.: Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study. Oncology, 59: 110, 2000
4. Aharinejad, S., Fink, M., Abri, H., Nedwed, S., Schlag, M. G., Macfelda, K. et al: Efficient carboplatin single therapy in a mouse model of human testicular nonseminomatous germ cell tumor. J Urol, 167: 368, 2002
5. Teicher, B. A., Sotomayor, E. A. and Huang, Z. D.: Anti-angiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res, 52: 6702, 1992
6. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A. et al: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA, 87: 6624, 1990
7. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S. et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277, 1997
8. Roberts, D. D., Cashel, J. A. and Guo, N. H.: Purification of thrombospondin from human platelets. J Tissue Culture Methods, 16: 217, 1994
9. Sambrook, J., Fritsch, E. F. and Maniatis, T.: Molecular Cloning A Laboratory Manual, 2nd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989
10. Aharinejad, S., Abraham, D., Paulus, P., Abri, H., Hofmann, M., Grossschmidt, K. et al: Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res, 62: 5317, 2002
11. Volpert, O. V., Lawler, J. and Bouck, N. P.: A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA, 95: 6343, 1998
12. Tolsma, S. S., Volpert, O. V., Good, D. J., Frazier, W. A., Polverini, P. J. and Bouck, N.: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol, 122: 497, 1993
13. Boehm, T., Folkman, J., Browder, T. and O'Reilly, M. S.: Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390: 404, 1997
14. Eisterer, W., Jiang, X., Bachelot, T., Pawliuk, R., Abramovich, C., Leboulch, P. et al: Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther, 5: 352, 2002
15. Campbell, S. C., Volpert, O. V., Ivanovich, M. and Bouck, N. P.: Molecular mediators of angiogenesis in bladder cancer. Cancer Res, 58: 1298, 1998
16. Rodriguez-Manzaneque, J. C., Lane, T. F., Ortega, M. A., Hynes, R. O., Lawler, J. and Iruela-Arispe, M. L.: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA, 98: 12485, 2001